MacuMira Receives Health Canada Approval for Novel AMD Treatment Device
Toronto, September 23, 2025 – MacuMira has announced the first Health Canada approval of its innovative device for the treatment of age-related macular degeneration (AMD), offering a new option for Canadians living with this leading cause of vision loss. The device, utilizing a proprietary technology, aims to improve visual function and quality of life for patients with both wet and dry forms of AMD.
This approval marks a critically important advancement in AMD treatment within Canada,where an aging population is experiencing a rising incidence of the disease. AMD affects the central part of the retina, leading to blurred or distorted vision, and ultimately, vision loss. Currently,treatment options are limited,often requiring frequent and invasive injections. MacuMira’s device presents a potentially less burdensome option, offering a new pathway for managing this debilitating condition.
Recent developments in the ophthalmic landscape include Sandoz licensing Lupin for a ranibizumab biosimilar – a Lucentis alternative – across Europe and Asia, as reported on September 23, 2025, by Ophthalmology Times. Additionally, Québec announced on August 19, 2025, that faricimab (Vabysmo, Roche) will be funded for macular edema secondary to retinal vein occlusion (RVO), as detailed in an Ophthalmology Times article by Harp MD. These approvals and funding decisions underscore a growing commitment to expanding treatment options for retinal diseases in the region.
